Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares reached a new 52-week low on Wednesday . The company traded as low as $13.32 and last traded at $13.45, with a volume of 726407 shares traded. The stock had previously closed at $13.75.

Wall Street Analysts Forecast Growth

KLRA has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings assumed coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The company has a 50-day moving average price of $17.18. The stock has a market cap of $1.68 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, research analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Kailera Therapeutics

Several large investors have recently bought and sold shares of KLRA. Tidal Investments LLC purchased a new stake in Kailera Therapeutics during the second quarter valued at $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics in the 2nd quarter worth $993,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics in the 2nd quarter worth $24,233,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Kailera Therapeutics in the 2nd quarter worth about $113,923,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at about $64,308,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.